CD49d (alpha chain of VLA-4) Antisense|Oligonucleotide clinical trials

A multicentre, randomised, double-blind, placebo-controlled and open label extension study to assess the efficacy, safety, and pharmacokinetic profile of two dose levels of ATL1102 administered by subcutaneous injection in nonambulatory participants with Duchenne Muscular Dystrophy

This study is looking at a new medicine called ATL1102 for Duchenne Muscular Dystrophy in boys who can't walk. It wants to see if the medicine helps improve arm and hand function and if it's safe. Some boys will get the real medicine, and some will get a dummy medicine at first.